• Corpus ID: 23850035

Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.

@article{Vermorken1984PharmacokineticsOF,
  title={Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.},
  author={Jan Baptist Vermorken and Wim J.F. van der Vijgh and Ina Klein and A A Hart and Helen E. Gall and Herbert Michael Pinedo},
  journal={Cancer treatment reports},
  year={1984},
  volume={68 3},
  pages={
          505-13
        }
}
Pharmacokinetic studies were performed in ten patients who received short-term (4-15-min) infusions of cisplatin. Computerized nonlinear least-squares analysis (NLIN) and an adapted curve-stripping approach (CSTRIP) were used to characterize total-platinum concentration-time curves. The overall curves showed a rapid initial phase and a prolonged terminal phase, separated by a phase with secondary peaks attributed to the existence of an enterohepatic recirculation. Up to Day 5, NLIN analysis… 
Long-term pharmacokinetic behavior of platinum after cisplatin administration
TLDR
A close equilibrium between ultrafiltrable and total platinum (ratio, 6%) persisted for as long as 3 weeks after cisplatin administration, underline the importance of individual differences in platinum metabolism.
A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors.
TLDR
The progressive enhancement of tissue exposure to the free cytotoxic drug, resulting from a reduced renal clearance of Pt with sequential courses of cisplatin, produced mainly increased toxicity while therapeutic effect progressively diminished.
Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin
TLDR
It is noteworthy that the mean values obtained for the terminal half0life, the volume of distribution, the renal clearance, the percentage of the dose excreted in the urine, and the mean residence time of total Pt were higher in patients who had been pretreated with GSH, suggesting that SGH might increase both the rate of Pt elimination and the extent of Pt distribution and, as a consequence of the latter, might prolong the residence time in the body.
Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial
TLDR
The human pharmacokinetic characteristics of ormaplatin resemble those of cisplatin; however, additional study will be required to discern which analyte of orMAplatin correlates best with clinical effects.
Cisplatin pharmacokinetics in children with cancer.
Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group
TLDR
A regional pharmacologic advantage was noted with carboplatin administered by this route, with peak peritoneal fluid concentrations 18-fold those in plasma, and area under the curve for the peritoneum showing a 4-fold and 6-fold increase over plasma AUC at 4 and 24 h, respectively.
Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
TLDR
The results suggest that the AUCp/AUCm ratio of free platinum over the first part of the concentration versus time curve can possibly be used to predict the maximal tolerated dose of platinum analogues in humans, during the early stage of phase I studies.
Clinical Pharmacokinetics of Carboplatin
TLDR
The pharmacokinetics, in vivo stability, protein binding, and elimination of carboplatin are distinct from the first‐generation analog cisplatin.
...
...

References

SHOWING 1-10 OF 14 REFERENCES
Clinical kinetics of intact cisplatin and some related species
TLDR
Larger doses of cisplatin resulted in higher plasma levels of all three species monitored, and although the increases appeared somewhat less than proportional to dose, terminal plasma slopes were not dose dependent.
Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs.
TLDR
Initial concentrations of platinum were highest in organs of excretion, gonads, spleen, and adrenals but remained significantly elevated only in kidney, liver, ovary, and uterus, where a tissue: plasma ratio of 3 to 4 was maintained for as long as 6 days posttreatment.
Cisplatin pharmacokinetics in a patient with renal dysfunction.
TLDR
The data show that the t1/2beta of DDP is prolonged three fold in a patient with profound renal failure, and the clinical implications of these findings await further studies.
Clinical and pharmacological studies with cis-diamminedichloroplatinum (II).
TLDR
Renal impairment was the dose-limiting toxicity in the single-dose escalation scheme used, and progressive renal failure contributed to the death of one patient, this Phase I investigation characterizes the toxicity and pharmacological disposition of the drug in 10 patients.
High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.
TLDR
The use of cisplatin at this dose schedule resulted in similar toxicity and pharmacokinetics when using hydration with either furosemide or mannitol, and animal studies suggest thatMannitol may be superior to furoSemide in this regard.
Kinetics of cis‐dichlorodiammineplatinum
TLDR
The cancer chemotherapeutic cis‐dichlorodiammineplatinum (cis‐DDP) was administered to 8 patients and the non‐protein‐bound platinum was found to be rapidly and biphasically cleared from the plasma with half‐life values of 8 to 10 min and 40 to 45 min.
Hematologic effects of cis-platinum-bleomycin therapy.
TLDR
In 1 patient marked hemolysis occurred over 10-day period associated with the appearance of irregular spherocytes on smear, a situation similar to the index case which initiated this study.
Parmacokinetic evidence for an enterohepatic circulation in a patient treated with cis dichloro diammine platinum II)
TLDR
Platinum concentrations in plasma were measured during and after a 15 min intravenous infusion of cis-dichlorodiamineplatium (II) (cis-platinum) at a dose of 100 mg/m2 to indicate the presence of an enterohepatic circulation.
Platinum levels in human erythrocytes following intravenous administration of cisplatin: importance of erythrocytes as a distribution site for platinum species.
TLDR
The in vivo studies indicated that the intracellular platinum levels are rapidly achieved following cisplatin administration and the platinum concentration appears to be linearly related to the administered dose, although the fraction of platinum found within the erythrocytes is slight.
...
...